| |
|
|
|
|
|
|
|
Trends in Medicinal
Chemistry
9th December 2010
NHLI,
Kensington, London |
|
Programme: |
|
09.00 |
Arrival, Registration
and Coffee |
|
|
|
Session 1 : Chair - Simon Ward, University of Sussex |
|
|
|
|
10.00
|
John E. Ladbury, Anderson Cancer
Center
ITC data in compound development |
|
10.55 |
David Millan, Pfizer
Biophysical
Techniques in Drug Design - A Medicinal Chemistry Perspective |
|
11.40 |
Nigel Parr, GSK
The structure based
optimisation of orally active MetAP-2 inhibitors for the treatment of
inflammation. |
|
|
|
|
12.25 |
Lunch
(including SMR AGM 13.05-13.25) |
|
|
|
|
Session 2 : Chair - Neil Hales, Allodigm |
|
|
|
|
13.30 |
Ann Eakin, AstraZeneca
Novel DNA Gyrase
Inhibitors: Fragment-Based NMR Screening to Antibacterial Agents |
|
14.15 |
Matthew Todd, Janssen Pharmaceuticals
Miniaturized Protein Thermal Stability
Measurements: from HTS to Lead Optimization |
|
|
|
|
15.00 |
Tea |
|
|
|
|
Session 3 : Chair - Phill Cowley, Merck |
|
|
|
|
15.30 |
Emmanuel Pinard, Roche
Selective GlyT1
Inhibitors: Discovery of RG1678, a Promising Novel Medicine to Treat
Schizophrenia |
|
16.15 |
Veronique Birault, GSK
Novel Allosteric
Modulators of the a7 Nicotinic Acetylcholine Receptor |
|
|
|
|
17.00 |
Close |
|
|
|
Back
to Menu
|
|
|
|
|
|
|
